PEB - Pacific Edge Ltd

[Arthur]

Thank you Retired Doctor.

[Carpenterjoe]

My 2c take is that CxBladder is a major disruptor and the AUA is likely a very conservative organisation. Also as you are likely aware the US health system bears a heavy litigation burden and there will be some anxiety re omitting an erstwhile gold standard procedure (cystoscopy) where you actually “have a look” and using a molecular test. What will likely weigh against persisting with cystoscopy is patient preference and the fact that there is a complication rate and morbidity with cystoscopy which although very low does raise the spectre of a lawyer asking in the situation of a cystoscopy gone wrong, why cystoscopy was done when a simple urine test would have sufficed.
I am not sure how the money flows in the US but cutting down on cystoscopies is going to decrease revenue for some urologists and hospitals/ clinics. Insurance companies should love CxB but again I donÂ’t know the details of the system.
I believe CxB is now popular in NZ urology practice and it wonÂ’t be far off penetrating primary care here albeit with some restrictions.
I feel confident that my modest PEB holding will grow but being largely ignorant of the economics of this I have no idea of by what factor the increasing numbers of tests will translate into profits. There will be others out there who may be able to comment on thatÂ…Â…Â…

Yip, guidelines move soooooo slow, when I first looked at this guideline, cxbladder had half a page on information. 5 years on we have 7 pages of information. At least it allows coverage in certain cases.

https://www.google.com/url?sa=t&sour...UKgyehz5aAvlae

[thegreatestben]

PACIFIC EDGE REPORTS CONTINUED GROWTH MOMENTUM INTO Q1 FY22
PACIFIC EDGE’S Q1 FY22 Update
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has reported a continuation of the positive growth momentum seen in the second half of the prior financial year, with sales of its Cxbladder tests continuing their strong growth.
The company, which is holding its Annual Meeting in Dunedin today, has delivered a record quarter in both test throughput and cash receipts for the three months from 1 April to 30 June 2021.
Laboratory throughput has risen consistently over the last five quarters
 179% on the same time last year
 109% increase on the preceding quarter (Q4 FY21)
Cash Receipts from Customers also continue to grow as reimbursement success and volumes grow.
 242% on the same time last year
 121% increase on the preceding quarter (Q4 FY21)
Growth Outlook
Pacific Edge has a positive growth outlook, with opportunities being addressed in each of its key markets. The priorities going forward are to firstly encourage commercial use of Cxbladder by large scale institutional healthcare organisations in each market; and secondly, to encourage customers to include multiple products from the Cxbladder suite of tests in their standard of care and mainstream commercial use.
The US remains the primary focus, with an annual addressable market of US$3.5 billion . With the Company’s recent commercial milestones achieved in reimbursement for tests, Pacific Edge has scaled up its sales team and resources in the US. An increasing number of commercial tests from the CMS, Kaiser Permanente and other scale payers such as United Healthcare are expected to underpin revenue and operating cashflow growth in FY22 and beyond. The company notes that the impact of the Covid-19 pandemic is still being felt, particularly restricted access to clinics and urologists for Pacific Edge’s sales team.
The focus in New Zealand is expanding the coverage by New Zealand’s public healthcare providers and continuing the evolution towards mainstream commercial use of more than one Cxbladder product. Australia and South East Asia are at an earlier stage in their commercial journey, with the goal being to transition the large scale public healthcare providers from clinical trials to a commercial customer model.
CEO David Darling said: “Our recent progress and commercial achievements over FY21 underpin our future growth. We are now seeing the commercial benefits of our efforts and the resources that have gone into the development and commercialisation of our Cxbladder technology, rolling into the company’s performance in the first quarter of FY22.”
ENDS

[Leftfield]

Great news for holders.

Laboratory throughput has risen consistently over the last five quarters
§ 179% on the same time last year
§ 109% increase on the preceding quarter (Q4 FY21)
Cash Receipts from Customers also continue to grow as reimbursement success and volumes grow.
§ 242% on the same time last year
§ 121% increase on the preceding quarter (Q4 FY21)

[Snow Leopard]

Easier to read the ann via the NZX website.

Specially good that cash receipts are well-up.

[pierre]

The good news journey continues.

We're not on a bullet train, but I think we're no longer on a roller coaster with PEB.

[winner69]

Great news for holders.

Laboratory throughput has risen consistently over the last five quarters
§ 179% on the same time last year
§ 109% increase on the preceding quarter (Q4 FY21)
Cash Receipts from Customers also continue to grow as reimbursement success and volumes grow.
§ 242% on the same time last year
§ 121% increase on the preceding quarter (Q4 FY21)

$100m sales before we know it

[Maxtrade]

Wonder why there is still a relatively large sell volume sitting around 1.25. If only those sellers would just remove or increase their sell price then the share price could continue on its merry way. Seems this block there is prevent the natural progression of the SP rallying. Let the good news take course.

Take a break sellers and let the bull run

[Leftfield]

$100m sales before we know it

Passed the 'point of inflection' maybe?

[Snow Leopard]

Easier to read the ann via the NZX website.

Specially good that cash receipts are well-up.

Amended notice

Not so well-up then . Cancel that reversing truck.